iX Biopharma Ltd.
Stock Exchange of SingaporeTotal Valuation
iX Biopharma Ltd. carries a market capitalization of 398.92M, placing it among publicly traded companies globally. Its enterprise value stands at 140.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 398.92M |
| Enterprise Value | 140.20M |
Share Statistics
iX Biopharma Ltd. currently has 664.27M shares outstanding.
| Shares Outstanding | 664.27M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 194.25, and the price-to-book ratio stands at 11.08.
| PE Ratio | N/A |
| PS Ratio | 194.25 |
| PB Ratio | 11.08 |
| P/TBV Ratio | 10.02 |
| P/FCF Ratio | -15.88 |
| P/OCF Ratio | -14.62 |
Enterprise Valuation
| EV / Sales | 185.45 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
iX Biopharma Ltd. maintains a current ratio of 4.87, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.26, indicating elevated leverage, while an interest coverage ratio of -49.68 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.87 |
| Quick Ratio | 4.14 |
| Debt / Equity | 27.26 |
| Debt / EBITDA | -0.36 |
| Interest Coverage | -49.68 |
Financial Efficiency
| Return on Equity (ROE) | -15.27 |
| Return on Assets (ROA) | -8.40 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.88 |
Taxes
| Income Tax | -5,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
iX Biopharma Ltd.'s stock has gained approximately 2105.88235% over the past 52 weeks. The 50-day moving average sits at 0.37, while the 200-day moving average is 0.21.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2105.88235% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.21 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, iX Biopharma Ltd. generated 756,000.00 in revenue and converted that into -1.91M in net income, yielding earnings per share of -0.02. EBITDA reached -11.48M, while operating income came in at -11.48M.
| Revenue | 756,000.00 |
| Gross Profit | -778,000.00 |
| Operating Income | -11.48M |
| Pretax Income | -12.09M |
| Net Income | -1.91M |
| EBITDA | -11.48M |
| EBIT | -11.48M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
iX Biopharma Ltd. holds 10.78M in cash and equivalents against 4.12M in total debt, resulting in a net debt position of -7.07M. Total book value stands at 13.25M, with working capital of 10.08M providing operational flexibility.
| Cash & Cash Equivalents | 10.78M |
| Total Debt | 4.12M |
| Net Debt | -7.07M |
| Equity (Book Value) | 13.25M |
| Book Value Per Share | 0.02 |
| Working Capital | 10.08M |
Cash Flow
iX Biopharma Ltd. produced -10.04M in operating cash flow over the past twelve months. After subtracting -760,000.00 in capital expenditures, free cash flow totaled -10.80M - equivalent to -0.02 per share.
| Operating Cash Flow | -10.04M |
| Capital Expenditures | -760,000.00 |
| Free Cash Flow | -10.80M |
| FCF Per Share | -0.02 |
Margins
iX Biopharma Ltd. operates with a gross margin of -102.91, reflecting its pricing power and cost economics. The operating margin of -1,517.99 and net profit margin of -253.04 provide insight into operational efficiency.
| Gross Margin | -102.91 |
| Operating Margin | -1,517.99 |
| Pretax Margin | -1,599.47 |
| Profit Margin | -253.04 |
| EBITDA Margin | -1,517.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 1.43 |
| FCF Yield | -6.30 |
Scores
iX Biopharma Ltd. posts an Altman Z-Score of 9.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.10 |